Company Overview
Capricor Therapeutics, Inc. operates as a clinical-stage biotechnology company dedicated to the development of transformative cell and exosome-based therapeutics designed to treat Duchenne muscular dystrophy (DMD) and other diseases characterized by unmet medical needs within the United States. The company functions within the broader Healthcare sector, specifically focusing on the Biotechnology industry, a domain defined by high innovation potential and significant reliance on clinical trial outcomes to generate future revenue streams. According to available financial data, the company holds a market capitalization of $1.66 billion and employs a workforce of 231 individuals to advance its research and development initiatives. The combination of a substantial market cap relative to its current revenue status and the absence of reported annual revenue indicates that the company is in a pre-revenue or early commercialization phase, where its primary asset value is derived from intellectual property, pipeline potential, and the capital raised to sustain operations until product milestones are achieved.
Financial Health
The company reports net income of $-105,043,944 and EBITDA of $-106,253,088 for the trailing twelve-month period, while revenue and price-to-sales figures are not available in current reporting, reflecting a typical burn rate for a clinical-stage entity. The significant disparity between the reported net income and the near-identical EBITDA figure reveals a cost structure where non-operating expenses or interest income/expense do not materially alter the core operating loss, highlighting that the majority of the financial loss stems from direct research, development, and administrative costs inherent in bringing therapeutics to market. Free cash flow stands at $-39,600,748, which underscores the company's consumption of cash reserves to fund its operations and R&D programs, thereby limiting immediate financial flexibility until revenue generation commences. All three key margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard presentation for biotechnology firms that have not yet achieved commercial sales, indicating that no gross profit is being generated to cover operating expenses or generate a net profit. Regarding liquidity and leverage, the company holds $318.13 million in cash against $14.52 million in debt, resulting in a debt-to-equity ratio of 4.75, which suggests a balance sheet that is heavily leveraged relative to equity but maintains a substantial cash buffer to cover obligations. The current ratio is reported at 9.01, indicating a very strong position in short-term liquidity where current assets significantly exceed current liabilities, providing ample room to manage working capital needs. Return on Equity is -46.6% and Return on Assets is -25.7%, metrics that reflect the dilutive effect of raising capital to fund negative earnings and losses rather than generating returns on the deployed capital base.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the absence of net income, while the forward P/E is listed as -75.97, a negative metric that implies the market is pricing in future earnings that are currently not expected to be profitable in the near term. The price-to-book ratio stands at 5.42, indicating that the market values the company at a significant premium over its book value, likely reflecting the high value placed on its intangible assets such as intellectual property and clinical pipeline rather than tangible physical assets. Alternative valuation metrics include an EV/EBITDA of -12.77 and a price-to-sales ratio that is N/A, suggesting that traditional multiple-based valuations are not applicable in the conventional sense and that valuation must be inferred through cash runway and pipeline valuation methods. The stock has traded between a 52-week high of $40.37 and a 52-week low of $4.30, representing a wide volatility range that suggests the current price is sensitive to clinical data releases and market sentiment regarding biotechnology sectors. With a beta of 0.48, the stock exhibits price volatility that is less than 50% of the broader market's movement, indicating a lower systematic risk profile compared to high-beta large-cap technology or financial stocks, though the high volatility range over the year suggests idiosyncratic risk specific to the company's development progress.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both N/A, as the company has not yet established a consistent history of revenue generation or profitable earnings growth typical of mature commercial enterprises. Consequently, the company does not distribute a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available cash flow is reinvested back into the business to fund clinical trials and operational expansion rather than being returned to shareholders. The absence of a dividend policy combined with the lack of historical growth rates characterizes the growth and income profile as purely capital appreciation-focused, where investor returns are contingent entirely on the successful commercialization of product candidates and the eventual transition from a cash-burning entity to a profitable one.